The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary.
 
Junko Tanizaki
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Taiho Pharmaceutical
Speakers' Bureau - AstraZeneca Japan
 
Kan Yonemori
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Novartis; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
 
Kohei Akiyoshi
No Relationships to Disclose
 
Hironobu Minami
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Takara Bio; Takeda
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Hiroki Ueda
No Relationships to Disclose
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
 
Chihiro Nakayama Kondoh
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Eisai; Janssen; Merck Sharp & Dohme; Nippon Shinyaku; Sanofi; Takeda
 
Yoshihiko Segawa
Honoraria - Taiho Pharmaceutical
Research Funding - Eisai; Taiho Pharmaceutical
 
Shin Takahashi
Honoraria - Asahi Kasei; Chugai Pharma; Daiichi Sankyo; Medicon; Merck Serono; Nihonkayaku; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Research Funding - Merck Serono; Ono Pharmaceutical
 
Yasuo Iwamoto
No Relationships to Disclose
 
Yasuhiro Kidera
No Relationships to Disclose
 
Kazuya Fukuoka
No Relationships to Disclose
 
Yasushi Nakamura
Consulting or Advisory Role - Mitsubishi Chemical Medience Corporation; Nikon Corporation
 
Yasutaka Chiba
Honoraria - Chugai Pharma
 
Kazuto Nishio
Speakers' Bureau - Chugai Pharma; Eisai; Nippon Boehringer Ingelheim; Novartis; Pfizer
 
Kazuhiko Nakagawa
Honoraria - Abbvie; Astellas Pharma; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Kyorin; Kyorin; Lilly; Medical Review Co., Ltd.; Medicus Shuppan Publishers; Medicus Shuppan Publishers; Merck; MSD K.K; NANZANDO Co.,Ltd.; Nichi-iko; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; YODOSHA; Yomiuri Telecasting Corporation
Consulting or Advisory Role - Kyorin; Lilly; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); ICON Clinical Research (Inst); IQvia (Inst); Kissei Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex